别名 ADENOCARCINOMA GASTRIC、Adenocarcinoma gastric、Adenocarcinoma of Stomach + [20] |
简介 An adenocarcinoma arising from the stomach glandular epithelium. Gastric adenocarcinoma is primarily a disease of older individuals. It most commonly develops after a long period of atrophic gastritis and is strongly associated with Helicobacter pylori infection. The lack of early symptoms often delays the diagnosis of gastric cancer. The majority of patients present with advanced tumors which have poor rates of curability. Microscopically, two important histologic types of gastric adenocarcinoma are recognized: the intestinal and diffuse type. The overall prognosis of gastric adenocarcinomas is poor, even in patients who receive a "curative" resection (adapted from Sternberg's Surgical Pathology, 3rd ed., 1999). |
靶点 |
作用机制 CLDN18.2抑制剂 [+2] |
在研适应症 |
最高研发阶段批准上市 |
首次获批国家/地区 日本 |
首次获批日期2024-03-26 |
靶点 |
作用机制 PD-1抑制剂 |
在研机构 |
原研机构 |
最高研发阶段批准上市 |
首次获批国家/地区 中国 |
首次获批日期2022-07-19 |
作用机制 CTLA4抑制剂 [+1] |
原研机构 |
最高研发阶段批准上市 |
首次获批国家/地区 中国 |
首次获批日期2022-06-28 |
开始日期2025-09-30 |
申办/合作机构 |
开始日期2024-06-11 |
申办/合作机构 |
开始日期2024-06-01 |
申办/合作机构- |